Luiz Eduardo Macedo Cardoso

Luiz Eduardo Macedo Cardoso

Auto-generated profile, based on publicly available information

Luiz Eduardo Macedo Cardoso

Laboratory of Morphometry, Metabolism, and Cardiovascular Disease, Institute of Biology, Biomedical Center, State University of Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 August 2021 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
TMThatiany de Souza Marinho
Thatiany de Souza Marinho
LCLuiz Eduardo de Macedo Cardoso
Luiz Eduardo de Macedo Cardoso
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila

1 February 2022 in Biochimie
Verified
Journal Article
Closed access
TMThatiany de Souza Marinho
Thatiany de Souza Marinho
MNManoel Ferreira Neto
Manoel Ferreira Neto
LCLuiz Eduardo de Macedo Cardoso
Luiz Eduardo de Macedo Cardoso
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda


8 February 2023 in Journal of Molecular Endocrinology
Verified
Journal Article
Closed access
PDF file
IMIlitch Aquino Marcondes-De-Castro
Ilitch Aquino Marcondes-De-Castro
TOThamiris Ferreira Oliveira
Thamiris Ferreira Oliveira
RSRenata Spezani
Renata Spezani
TMThatiany Souza Marinho
Thatiany Souza Marinho
LCLuiz Eduardo Macedo Cardoso
Luiz Eduardo Macedo Cardoso
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
Obesity, adipose tissue inflammation, and nonalcoholic fatty liver disease (NAFLD) are associated with insulin resistance and type 2 diabetes (T2D). Cotadutide is a dual agonist GLP-1/glucagon, currently in a preclinical study phase 2 that presents an anti-obesity effect. Diet-induced obese (DIO) C57BL/6 mice were treated for 4 weeks with cotadutide (30 nm/kg once a day at 14:00 h). The study focused on epididymal white adipose tissue (eWAT), liver (NAFLD), inflammation, lipid metabolism, AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) pathways, and the endoplasmic reticulum (ER) stress. As a result, cotadutide controlled weight gain, glucose intolerance, and insulin resistance and showed beneficial effects on plasma markers in DIO mice (triacylglycerol, total cholesterol, alanine aminotransferase, and aspartate aminotransferase, leptin, adiponectin, monocyte chemoattractant protein-1, resistin, interleukin-6, tumor necrosis factor-alpha). Also, cotadutide lessened liver fat accumulation, eWAT proinflammatory markers, and ER stress. In addition, cotadutide improved lipid metabolism genes in eWAT, fatty acid synthase, peroxisome proliferator-activated receptor gamma and mitigates adipocyte hypertrophy and apoptosis. Furthermore, the effects of cotadutide were related to liver AMPK/mTOR pathway and ER stress. In conclusion, cotadutide induces weight loss and treats glucose intolerance and insulin resistance in DIO mice. In addition, cotadutide shows beneficial effects on liver lipid metabolism, mitigating steatosis, inflammation, and ER stress. Besides, in adipocytes, cotadutide decreases hypertrophy and reduces apoptosis. These actions rescuing the AMPK and mTOR pathway, improving lipid metabolism, and lessening NAFLD, inflammation, and ER stress in both eWAT and liver of DIO mice indicate cotadutide as a potentially new pharmacological treatment for T2D and associated obesity.

1 May 2002
Verified
Journal Article
Closed access
WCWaldemar S Costa
Waldemar S Costa
FSFrancisco J B Sampaio
Francisco J B Sampaio
LFLuciano A Favorito
Luciano A Favorito
LCLuiz E M Cardoso
Luiz E M Cardoso